HALOHALOZYME THERAPEUTICS, INC.同业对比
HALOZYME THERAPEUTICS, INC. 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HALO本股 | $12.8B#2 | 33.0x#1 | 89.0x#12 | 9.1x#1 | 37.6%#4 | -28.6%#8 | 33.6%#1 | 220.8%#1 | 15.0%#1 | — | 46.7%#10 | — |
| MRNA | $61.5B#1 | — | 9.1x#7 | 31.6x#3 | -39.9%#7 | 20.8%#5 | -158.1%#4 | -41.7%#11 | -54.6%#4 | — | 504.1%#4 | — |
| TWST | $10.5B#3 | — | 23.5x#10 | 27.8x#2 | 20.3%#5 | 62.8%#1 | -36.2%#2 | -17.4%#7 | -41.4%#3 | — | 497.4%#5 | — |
| ORKA | $6.3B#10 | — | 5.6x#2 | — | — | -25.9%#7 | — | -9.5%#5 | — | — | 472.3%#6 | — |
| KYMR | $9.8B#4 | — | 6.5x#5 | 249.8x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 20.6%#2 | — | — | 130.3%#7 | — |
| VKTX | $3.4B#12 | — | 8.3x#6 | — | — | -227.1%#13 | — | -88.1%#12 | — | — | 11.3%#12 | — |
| PRAX | $8.4B#7 | — | 6.2x#3 | — | -100.0%#8 | -65.6%#11 | — | -22.6%#9 | — | — | 561.0%#3 | — |
| ERAS | $5.2B#11 | — | 14.3x#8 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | 688.8%#1 | — |
| RYTM | $6.7B#8 | — | 65.2x#11 | 35.4x#4 | 45.8%#3 | 24.6%#3 | -101.2%#3 | -0.2%#4 | -133.8%#5 | — | -1.1%#13 | — |
| CGON | $6.6B#9 | — | 6.4x#4 | 1639.6x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#6 | -18.8%#2 | — | 92.5%#8 | — |
| SLS | $2.3B#13 | — | 16.9x#9 | — | -100.0%#8 | 13.0%#6 | — | -19.5%#8 | — | — | 616.5%#2 | — |
| PCVX | $8.7B#6 | — | 3.1x#1 | — | — | -65.2%#10 | — | -0.0%#3 | — | — | 78.5%#9 | — |
| CYTK | $9.6B#5 | — | — | 108.5x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | 39.3%#11 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-19。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议